Clinical Trial Update: Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thrombocytopenia [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating subcutaneous belimumab or placebo added to rituximab for persistent or chronic immune thrombocytopenia; currently recruiting with effic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Belimumab (belimumab)
• Rituximab (rituximab)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Primary Immune Thrombocytopenia (ITP) | Phase 3 | Status: RECRUITING